630
Participants
Start Date
June 16, 2017
Primary Completion Date
June 1, 2026
Study Completion Date
June 1, 2026
Questionnaires
Questionnaires completed at baseline and at 6 weeks, 12 weeks, and 6 months after the CT scan.
Low Dose Computed Tomography Scan
Participants have a CT scan of chest to look for signs of lung cancer.
Shared Decision Making + Video
Participants given shared decision making and discussion about screening with the LDCT provider. Participants watch a short video about lung cancer, CT scans, and smoking cessation.
Cessation Counseling
Brief cessation counseling given by LDCT provider.
Quitline
Participants referred to the Quitline for counseling. Participants have 5 smoking cessation counseling sessions over the next 12 weeks.
Pharmacotherapy Discussion
Participant informed of the risk, benefits and relative efficacy of cessation medications and to assess their medication preferences, expectations and medical suitability for either option. At the conclusion of this conversation the patient is provided with an initial supply of the medication jointly decided between provider and patient.
Nicotine Patch
Nicotine patch dispensed. Dosing at physician's discretion.
Anti-Smoking Drug
Varenicline or Buproprion prescribed by study doctor with directions of when and how much of anti-smoking drug that should be taken each time.
Tobacco Treatment Program
Participant referred to Tobacco Treatment Program (TTP). TTP provides 4-8 counseling sessions and pharmacotherapy over a 10-12 week period,
Carbon Monoxide (CO) Level Test
Participant asked to blow air through a CO-measuring device.
University of Texas MD Anderson Cancer Center, Houston
Collaborators (1)
National Cancer Institute (NCI)
NIH
Pfizer
INDUSTRY
M.D. Anderson Cancer Center
OTHER